Celcuity Inc.

CELC (NasdaqCM)

Celcuity Inc. is a clinical-stage biotechnology company focused on targeted therapies for solid tumors in the United States. Its lead candidate, Gedatolisib, inhibits selective Class I PI3K isoforms and the mTORC1/mTORC2 complexes to treat HR+/HER2− or HR+/HER2− advanced or metastatic breast cancer and metastatic castration-resistant prostate cancer. Celcuity previously licensed Gedatolisib from Pfizer. Founded in 2011, based in Minneapolis, Minnesota.